0000899243-19-002326.txt : 20190201 0000899243-19-002326.hdr.sgml : 20190201 20190201164047 ACCESSION NUMBER: 0000899243-19-002326 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190131 FILED AS OF DATE: 20190201 DATE AS OF CHANGE: 20190201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JOHNSON KENNETH ERLAND CENTRAL INDEX KEY: 0001743774 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38536 FILM NUMBER: 19560330 MAIL ADDRESS: STREET 1: C/O XERIS PHARMACEUTICALS, INC. STREET 2: 180 N. LASALLE STREET, SUITE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001346302 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203352427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: STE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 BUSINESS PHONE: 512-498-2670 MAIL ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: STE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-31 0 0001346302 XERIS PHARMACEUTICALS INC XERS 0001743774 JOHNSON KENNETH ERLAND C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1810 CHICAGO IL 60601 0 1 0 0 See Remarks Stock Option (right to buy) 13.88 2019-01-31 4 A 0 32500 0.00 A 2029-01-31 Common Stock 32500 32500 D 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Senior Vice President Clinical Development, Quality Assurance, and Medical Affairs /s/ Beth Hecht, as Attorney-in-Fact 2019-02-01